ImmuCell (ICCC) Revenue & Revenue Breakdown

OverviewOwnership Financials Chart Transcripts

ImmuCell Revenue Highlights

Latest Revenue (Y)

$17.47M

Latest Revenue (Q)

$6.01B

Main Segment (Y)

FirstDefenseProductLineMember

Main Geography (Y)

FirstDefenseProductLineMember

ImmuCell Revenue by Period

ImmuCell Revenue by Year

Date	Revenue	Change
2023-12-31	$17.47M	-5.90%
2022-12-31	$18.57M	-3.51%
2021-12-31	$19.24M	25.43%
2020-12-31	$15.34M	11.80%
2019-12-31	$13.72M	24.91%
2018-12-31	$10.99M	5.32%
2017-12-31	$10.43M	9.29%
2016-12-31	$9.54M	-6.69%
2015-12-31	$10.23M	34.64%
2014-12-31	$7.60M	26.46%
2013-12-31	$6.01M	11.45%
2012-12-31	$5.39M	5.45%
2011-12-31	$5.11M	16.53%
2010-12-31	$4.39M	-2.72%
2009-12-31	$4.51M	-2.70%
2008-12-31	$4.63M	-23.65%
2007-12-31	$6.07M	26.41%
2006-12-31	$4.80M	-3.65%
2005-12-31	$4.98M	34.82%
2004-12-31	$3.70M	10.10%
2003-12-31	$3.36M	-45.72%
2002-12-31	$6.18M	-7.37%
2001-12-31	$6.68M	18.47%
2000-12-31	$5.64M	14.80%
1999-12-31	$4.91M	9.09%
1998-12-31	$4.50M	-2.17%
1997-12-31	$4.60M	4.55%
1996-12-31	$4.40M	-10.20%
1995-12-31	$4.90M	11.36%
1994-12-31	$4.40M	12.82%
1993-12-31	$3.90M	-

ImmuCell generated $17.47M in revenue during NA 2023, up -5.90% compared to the previous quarter, and up 159.04% compared to the same period a year ago.

ImmuCell Revenue by Quarter

Date	Revenue	Change
2024-09-30	$6.01B	109742.75%
2024-06-30	$5.47M	-24.59%
2024-03-31	$7.26M	42.42%
2023-12-31	$5.10M	-5.57%
2023-09-30	$5.40M	52.76%
2023-06-30	$3.53M	2.50%
2023-03-31	$3.45M	-11.87%
2022-12-31	$3.91M	-18.45%
2022-09-30	$4.80M	24.20%
2022-06-30	$3.86M	-35.64%
2022-03-31	$6.00M	10.21%
2021-12-31	$5.44M	5.70%
2021-09-30	$5.15M	13.39%
2021-06-30	$4.54M	10.58%
2021-03-31	$4.11M	9.73%
2020-12-31	$3.74M	0.55%
2020-09-30	$3.72M	25.51%
2020-06-30	$2.97M	-39.60%
2020-03-31	$4.91M	35.20%
2019-12-31	$3.63M	22.27%
2019-09-30	$2.97M	9.61%
2019-06-30	$2.71M	-38.56%
2019-03-31	$4.41M	50.17%
2018-12-31	$2.94M	36.37%
2018-09-30	$2.15M	-28.55%
2018-06-30	$3.01M	4.63%
2018-03-31	$2.88M	-8.04%
2017-12-31	$3.13M	56.26%
2017-09-30	$2.00M	14.60%
2017-06-30	$1.75M	-50.63%
2017-03-31	$3.54M	60.08%
2016-12-31	$2.21M	12.48%
2016-09-30	$1.97M	-17.15%
2016-06-30	$2.38M	-20.45%
2016-03-31	$2.99M	10.84%
2015-12-31	$2.69M	8.98%
2015-09-30	$2.47M	26.12%
2015-06-30	$1.96M	-36.79%
2015-03-31	$3.10M	40.64%
2014-12-31	$2.21M	24.58%
2014-09-30	$1.77M	14.96%
2014-06-30	$1.54M	-26.04%
2014-03-31	$2.08M	33.51%
2013-12-31	$1.56M	26.29%
2013-09-30	$1.23M	-9.64%
2013-06-30	$1.37M	-26.00%
2013-03-31	$1.85M	29.96%
2012-12-31	$1.42M	31.97%
2012-09-30	$1.08M	-8.37%
2012-06-30	$1.18M	-31.56%
2012-03-31	$1.72M	31.62%
2011-12-31	$1.30M	30.01%
2011-09-30	$1.00M	-19.56%
2011-06-30	$1.25M	-19.81%
2011-03-31	$1.56M	38.82%
2010-12-31	$1.12M	28.26%
2010-09-30	$873.72K	-19.04%
2010-06-30	$1.08M	-17.75%
2010-03-31	$1.31M	26.88%
2009-12-31	$1.03M	2.23%
2009-09-30	$1.01M	1.03%
2009-06-30	$1.00M	-31.48%
2009-03-31	$1.46M	17.13%
2008-12-31	$1.25M	35.04%
2008-09-30	$924.00K	11.82%
2008-06-30	$826.30K	-49.48%
2008-03-31	$1.64M	8.84%
2007-12-31	$1.50M	-

ImmuCell generated $6.01B in revenue during Q3 2024, up 109742.75% compared to the previous quarter, and up 170170.28% compared to the same period a year ago.

ImmuCell Revenue Breakdown

ImmuCell Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 21
FirstDefenseProductLineMember	$18.93M
OtherAnimalHealthMember	$309.88K

ImmuCell's latest annual revenue breakdown by segment (product or service), as of Dec 21: FirstDefenseProductLineMember (98.39%), and OtherAnimalHealthMember (1.61%).

Quarterly Revenue by Product

Product/Service	Dec 21	Sep 21	Jun 21	Jun 18	Mar 18
OtherAnimalHealthMember	$40.59K	$116.75K	$68.86K	-	-
FirstDefenseProductLineMember	$5.40M	$5.03M	$4.47M	-	-
First Defense Product Line	-	-	-	$2.88M	$2.78M
Other Animal Health	-	-	-	$131.06K	$100.32K

ImmuCell's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: FirstDefenseProductLineMember (99.25%), and OtherAnimalHealthMember (0.75%).

ImmuCell Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 21
FirstDefenseProductLineMember	$18.93M
OtherAnimalHealthMember	$309.88K
UNITED STATES	$16.62M
OtherStatesMember	$2.62M

ImmuCell's latest annual revenue breakdown by geography, as of Dec 21: FirstDefenseProductLineMember (49.19%), UNITED STATES (43.19%), OtherStatesMember (6.81%), and OtherAnimalHealthMember (0.81%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Sep 23	Dec 21	Sep 21	Jun 21	Jun 18	Mar 18
UNITED STATES	$5.22M	$4.89M	$6.34M	$4.92M	$4.46M	$4.55M	$4.03M	-	-
FirstDefenseProductLineMember	-	-	-	-	$5.40M	-	-	-	-
OtherStatesMember	-	-	-	-	$984.57K	$599.83K	$511.57K	-	-
OtherAnimalHealthMember	-	-	-	-	$40.59K	-	-	-	-
United States	-	-	-	-	-	-	-	$2.54M	$2.60M
Other States	-	-	-	-	-	-	-	$470.41K	$285.57K

ImmuCell's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (100.00%).

ImmuCell Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
LIPO	Lipella Pharmaceuticals	$449.62M	$80.38M
FENC	Fennec Pharmaceuticals	$21.64M	$6.97M
ICCC	ImmuCell	$17.47M	$6.01B
HCWB	HCW Biologics	$2.84M	$426.42K
MNOV	MediciNova	$1.00M	-
ANEB	Anebulo Pharmaceuticals	-	-
RZLT	Rezolute	-	-
CYT	Cyteir Therapeutics	-	-
ELYM	Eliem Therapeutics	-	-
CVKD	Cadrenal Therapeutics	-	-
TPST	Tempest Therapeutics	-	-
PTIX	Protagenic Therapeutics	-	$50.29K

ICCC Revenue FAQ

What is ImmuCell’s yearly revenue?

ImmuCell's yearly revenue for 2023 was $17.47M, representing a decrease of -5.90% compared to 2022. The company's yearly revenue for 2022 was $18.57M, representing a decrease of -3.51% compared to 2021. ICCC's yearly revenue for 2021 was $19.24M, representing an increase of 25.43% compared to 2020.

What is ImmuCell’s quarterly revenue?

ImmuCell's quarterly revenue for Q3 2024 was $6.01B, a 109742.75% increase from the previous quarter (Q2 2024), and a 111297.63% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $5.47M, a -24.59% decrease from the previous quarter (Q1 2024), and a 54.92% increase year-over-year (Q2 2023). ICCC's quarterly revenue for Q1 2024 was $7.26M, a 42.42% increase from the previous quarter (Q4 2023), and a 110.58% increase year-over-year (Q1 2023).

What is ImmuCell’s revenue growth rate?

ImmuCell's revenue growth rate for the last 3 years (2021-2023) was -9.20%, and for the last 5 years (2019-2023) was 27.32%.

What are ImmuCell’s revenue streams?

ImmuCell's revenue streams in c 21 are FirstDefenseProductLineMember, and OtherAnimalHealthMember. FirstDefenseProductLineMember generated $18.93M in revenue, accounting 98.39% of the company's total revenue OtherAnimalHealthMember generated $309.88K in revenue, accounting 1.61% of the company's total revenue

What is ImmuCell’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of ImmuCell was FirstDefenseProductLineMember. This segment made a revenue of $18.93M, representing 98.39% of the company's total revenue.